

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.		SERIAL NO.
	20609/203 (PD 00034)		Division of 10/106,521
	APPLICANT		
	Miller et al.		
	FILING DATE		GROUP ART UNIT
	Herewith		To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
CA	1	3,940,387	02/24/1976	Saint-Ruf et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

CA	2	Portoghese et al., "Stereostructure-Activity Relationship of Opioid Agonist and Antagonist Bivalent Ligands. Evidence for Bridging Between Vicinal Opioid Receptors," <u>J. Med. Chem.</u> 28:1140-41 (1985)
CA	3	Erez et al., "Narcotic Antagonist Potency of Bivalent Ligands Which Contain β -Naltrexamine. Evidence for Bridging Between Proximal Recognition Sites," <u>J. Med. Chem.</u> 25:847-849 (1982)
CA	4	Philip S. Portoghese, "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands," <u>Journal of Medicinal Chemistry</u> 35(11):1927-1937 (1992)
CA	5	Philip S. Portoghese, "Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists," <u>TIPS Review</u> 10:230-235 (1989)
CA	6	Shimohigashi et al., "Dimeric Tetrapeptide Enkephalins Display Extraordinary Selectivity for the δ Opiate Receptor," <u>Nature</u> 297:333-335 (1982)
CA	7	LeBoulluec et al., "Bivalent Indoles Exhibiting Serotonergic Binding Affinity," <u>Bioorganic & Medicinal Chemistry Letters</u> , 5:123-126 (1995)
CA	8	Cwirla et al., "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <u>Science</u> 276:1696-1699 (1997)
EXAMINER		DATE CONSIDERED
AULAKH		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 20609/203 (PD 00034)	SERIAL NO. Division of 10/106,521
	APPLICANT Miller et al.	
	FILING DATE Herewith	GROUP ART UNIT To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

CA		9	Uhlén et al., "Membrane Organization and Mobility of α_2 Adrenergic Receptors in MDCK Cells,"
			<u>Pharmacology Communications</u> 6(1-3):155-167 (1995)
CA		10	Maggio et al., "Coexpression Studies with Mutant Muscarinic/Adrenergic Receptors Provide Evidence for Intermolecular
			"Cross-Talk" Between G-Protein-Linked Receptors," <u>Proc. Natl. Acad. Sci. USA</u> 90:3103-3107 (1993)
CA		11	Maggio et al., "Functional Role of the Third Cytoplasmic Loop in Muscarinic Receptor Dimerization,"
			<u>The Journal of Biological Chemistry</u> 271(49):31055-31060 (1996)
CA		12	Zheng, et al., "Yohimbine Dimers Exhibiting Binding Selectivities for Human α_{2A} - versus α_{2B} -Adrenergic Receptors," <u>Biorg.</u>
			<u>Med. Chem. Lett.</u> 10:627-630 (2000)
EXAMINER			DATE CONSIDERED
AULAKH			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			